• Revolution Medicines CFO Jack Anders reported a net reduction in common-stock holdings tied to option exercise and share sales on June 24, 2026.
• Exercised stock options for 20,000 shares at USD 18.56.
• Sold 20,000 shares at weighted-average prices from USD 167.35 to USD 170.32.
• Beneficial ownership in common stock stood at 123,269 shares following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001610717-26-000296), on June 26, 2026, and is solely responsible for the information contained therein.